Caladrius Biosciences, Inc. CLBS
Day range unavailable
52-week range unavailable
- Market cap
- 25.83M
- Shares out
- 60.58M
- Forward P/E
- -1.18
- Beta
- 0.91
- Analysts
- Buy
- Price target
- 4.50 (+955.3%)
- Earnings date
- Nov 3, 2022
Key statistics
- Enterprise value
- -41.77M
- PEG ratio
- -0.02
- Price / sales
- 0.00
- Price / book
- 0.31
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- -15.18M
- Total cash
- 72.99M
- Total debt
- 561.00K
- Return on equity
- -26.31%
- Short % of float
- 0.81%
- 50-day average
- 7.53
- 200-day average
- 9.41
Analyst view
Consensus: buy
- Target (low)
- 3.00
- Target (mean)
- 4.50
- Target (high)
- 6.00
- Strong buy0
- Buy2
- Hold0
- Sell0
- Strong sell0
Next earnings
Nov 3, 2022
Expected Nov 3, 2022. Consensus EPS estimate -0.12.
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 3, 2022 | Sep 1, 2022 | -0.12 | — | — | — |
| Aug 4, 2022 | Jun 1, 2022 | -0.10 | — | — | — |
| May 5, 2022 | Mar 1, 2022 | -0.10 | — | — | — |
| Mar 22, 2022 | Dec 1, 2021 | -0.15 | — | — | — |
| Nov 4, 2021 | Sep 1, 2021 | -0.13 | — | — | — |
| Aug 5, 2021 | Jun 1, 2021 | -0.15 | — | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Mar 23, 2022 | HC Wainwright & Co. | main | — | Buy |
| Mar 3, 2021 | Brookline Capital | main | — | Buy |
| May 14, 2019 | WBB Securities | init | — | Speculative Buy |
| Mar 23, 2018 | Chardan Capital | main | Buy | Buy |
| Mar 7, 2018 | H.C. Wainwright | main | Buy | Buy |
| Aug 23, 2016 | Chardan Capital | init | — | Buy |
About Caladrius Biosciences, Inc.
Caladrius Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing cellular therapies to reverse disease and/or promote the regeneration of damaged tissue. Its product candidates include HONEDRA, a recipient of SAKIGAKE designation that is in Phase II clinical trial for the treatment of critical limb ischemia; XOWNA that is in Phase IIb clinical trial for the treatment of coronary microvascular dysfunction; and CLBS201, a CD34+ cell therapy for the treatment of pre-dialysis patients with chronic kidney disease. The company was formerly known as NeoStem, Inc. and changed its name to Caladrius Biosciences, Inc. in June 2015. Caladrius Biosciences, Inc. was incorporated in 1980 and is headquartered in Basking Ridge, New Jersey.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- caladrius.com
News
Why Vintage Wine Estates Shares Tumbled 40%; Here Are 70 Biggest Movers From Yesterday 
Stocks That Hit 52-Week Lows On Wednesday - Earnings Scheduled For August 4, 2022
Earnings Scheduled For May 5, 2022 
Stocks That Hit 52-Week Lows On Thursday 
Earnings Scheduled For March 22, 2022 - Earnings Scheduled For November 4, 2021
- Stocks That Hit 52-Week Lows On Tuesday
- Earnings Scheduled For August 5, 2021
- Earnings Scheduled For May 6, 2021
Your note
Sign in to keep a note on CLBS — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BROWN GREGORY B | Director | Stock Award(Grant) | Jan 9, 2022 | 149,040 |
| BUCK KRISTEN K | Officer | Stock Award(Grant) | Aug 31, 2022 | 307,244 |
| DAVIDSON MICHAEL H | Director | Stock Award(Grant) | Jan 9, 2022 | 209,753 |
| FLOWERS CYNTHIA LOUISE | Director | Stock Award(Grant) | Jan 9, 2022 | 145,847 |
| GIROLAMO TODD C. J.D. | Officer | Stock Award(Grant) | Jan 9, 2022 | 165,548 |
| KLOSK STEVEN MARK | Director | Stock Award(Grant) | Jan 9, 2022 | 151,390 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Group, Inc. (The) | 4.37% | 2,644,608 | 1.13M | Jun 29, 2022 |
| Sabby Management, LLC | 3.87% | 2,343,991 | 999.48K | Jun 29, 2022 |
| Renaissance Technologies, LLC | 2.68% | 1,623,580 | 692.29K | Jun 29, 2022 |
| Blackrock Inc. | 1.41% | 852,624 | 363.56K | Jun 29, 2022 |
| RA Capital Management, L.P. | 1.24% | 752,500 | 320.87K | Jun 29, 2022 |
| Geode Capital Management, LLC | 0.64% | 390,625 | 166.56K | Jun 29, 2022 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 2.93% | 1,775,055 | 756.88K | Jun 29, 2022 |
| Vanguard Extended Market Index Fund | 1.40% | 850,585 | 362.69K | Jun 29, 2022 |
| Fidelity Extended Market Index Fund | 0.39% | 237,040 | 101.07K | Jun 29, 2022 |
| Fidelity Series Total Market Index Fund | 0.09% | 51,793 | 22.08K | Jun 29, 2022 |
| Fidelity Total Market Index Fund | 0.08% | 48,949 | 20.87K | Jun 29, 2022 |
| Fidelity NASDAQ Composite Index Fund | 0.05% | 30,152 | 12.86K | Jun 29, 2022 |